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Abstract
Ribosomes and protein synthesis have been reported to be altered in the cerebral cortex at
advanced stages of Alzheimer’s disease (AD). Modifications in the hippocampus with
disease progression have not been assessed. Sixty-seven cases including middle-aged (MA)
and AD stages I–VI were analyzed. Nucleolar chaperones nucleolin, nucleophosmin and
nucleoplasmin 3, and upstream binding transcription factor RNA polymerase I gene (UBTF)
mRNAs are abnormally regulated and their protein levels reduced in AD. Histone
modifications dimethylated histone H3K9 (H3K9me2) and acetylated histone H3K12
(H3K12ac) are decreased in CA1. Nuclear tau declines in CA1 and dentate gyrus (DG), and
practically disappears in neurons with neurofibrillary tangles. Subunit 28 ribosomal RNA
(28S rRNA) expression is altered in CA1 and DG in AD. Several genes encoding ribosomal
proteins are abnormally regulated and protein levels of translation initiation factors eIF2a,
eIF3h and eIF5, and elongation factor eEF2, are altered in the CA1 region in AD. These
findings show alterations in the protein synthesis machinery in AD involving the nucleolus,
nucleus and ribosomes in the hippocampus in AD some of them starting at first stages (I–II)
preceding neuron loss. These changes may lie behind reduced numbers of dendritic branches
and reduced synapses of CA1 and DG neurons which cause hippocampal atrophy.
INTRODUCTION
Alzheimer’s disease (AD) is characterized clinically by progressive
loss of memory and cognitive decline leading to dementia, and histo-
phalogicaly by atrophy of the brain typically involving the hippocam-
pus and medial region of the temporal lobes even at early stages of
the disease. The neuropathological markers are on one hand, phos-
phorylated and truncated tau that deposit in the form of neurofibril-
lary tangles (NFTs), neuropil threads and plaque-surrounding
dystrophic neurites and, on the other hand, extracellular b-amyloid
that deposits in the form of diffuse and neuritic or senile plaques, and
in the walls of blood vessels. At initial asymptomatic stages, NFTs in
the cerebrum are restricted to the transentorhinal and entorhinal corti-
ces and CA1 region of the hippocampus. Later on, NFTs spread to
the amygdala, and nuclei of the forebrain and the whole neocortex,
among other areas. Although following a distinct pattern, b-amyloid
deposits also spread from the basal regions of the cerebrum to cover
practically the entire telencephalon (10). Examination of large series
of post-mortem brains has shown that AD-related pathology, at least
at stages I-II and III of Braak and Braak, occurs in about 80% of indi-
viduals aged 65 years, while only about 5% have the extensive
lesions that correspond to stages IV, V or VI and manifest cognitive
impairment and dementia (11–13, 35). Progression of NFTs and pla-
ques accompanied by cerebral atrophy is causative of severe cogni-
tive impairment and dementia in about 25% of human beings aged
80 years. Therefore, AD is a progressive neurodegenerative process
developing over many years and not necessarily leading to dementia
(35). The silent period, if properly detected, would permit the admin-
istration of therapies geared to curbing disease progression before the
magnitude of nerve tissue damage is too extensive. One of the most
commonly used markers to verify disease progression is neuroimag-
ing examination of the hippocampal formation to detect early atrophy
in this region (3, 5, 8, 16, 20, 23, 54, 63).
Hippocampal atrophy in AD has been interpreted as secondary
to neurofibrillary tangle formation, neuron atrophy and loss of neu-
rons. However, the cause of neuron atrophy has not been examined
in detail although one of the most plausible causes is reduced pro-
tein synthesis. Seminal studies identified altered composition of
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ribosomes and abnormal expression levels of certain transcription
factors, and impaired protein synthesis in cortical areas in cases
with mild cognitive impairment and dementia caused by AD (26,
34, 62, 64, 84). The main modifications were reduced rRNA
levels, increased RNA oxidation as shown by increased
8-hydroxyguanosine immunoreactivity, and reduced capacity of
isolated polyribosomes to incorporate S35 methionine into protein
(26, 27, 48, 75, 76, 90, 91). Moreover, the nuclear organizer region
(NOR) surface/total nucleus surface is reduced (22, 28), and the
rDNA promoter is hyper-methylated in AD, thus suggesting epige-
netic silencing of rDNA at very precise times of AD progression
(80). Together, these findings suggest a complex scenario in which
several pathways, from the nucleus and nucleolus to the ribosome,
are altered in the cerebral cortex in AD.
This study analyzes expression of mRNAs of genes playing an
important role in nucleolar function and rRNA biosynthesis, protein
levels and localization, rRNA levels, mRNA expression of several
ribosomal proteins, expression of selected histones involved in nucle-
olar processing, and expression levels of initiation and elongation
factors of protein synthesis in the CA1 region and dentate gyrus
(DG) of the hippocampus in middle-aged individuals (MA) and AD
cases stages I–II, III–IV and V–VI. The aim of the study was to
assess in parallel in the same cases, (i) possible alterations of the path-
ways involved in protein synthesis; (ii) changes at very early stages
of the disease in which changes cannot be attributed to neuron loss in
comparison with changes observed at advanced stages of the disease;
and (iii) possible differences in the CA1 region and the DG, the first
one with development of NFTs and the second without, but both




Brain samples were obtained from the Institute of Neuropathology
HUB-ICO-IDIBELL Biobank following European Union legislation
and the approval of the local ethics committee. The time from death
to tissue processing (post-mortem delay) was between 3 and 18 h. At
autopsy, one hemisphere was rapidly cut in coronal sections 1-cm
thick and selected areas of the encephalon were dissected, frozen on
dry ice, and stored at 2808C into labeled plastic bags until use. The
other hemisphere was fixed by immersion in 4% buffered formalin
for 3 weeks for morphologic examination. Neuropathological study
was performed on 25 regions of the cerebral cortex, diencephalon,
thalamus, brainstem and cerebellum. Dewaxed paraffin sections were
stained with haematoxylin and eosin and Kl€uver-Barrera, and proc-
essed for immunohistochemistry to microglia specific markers, glial
fibrillary acidic protein, b-amyloid, phosphorylated tau, a-synuclein,
TDP-43, ubiquitin and p62. Neuropathological diagnosis of AD was
performed following the Braak and Braak stages (10, 12) adapted to
paraffin sections (9).
The AD cases included in the present study were 16 stages I–II
(4 women, 12 men), 16 stages III–IV (9 women, 7 men) and 17
stages V–VI (9 women, 8 men). Cases with additional pathologies,
including Lewy body diseases, tauopathies (particularly argyro-
philic grain disease), vascular diseases, TDP-43pathies, and meta-
bolic syndrome were excluded. MA cases (n 5 18) had not
suffered from neurologic or psychiatric diseases, and did not have
lesions in the neuropathological study (including vascular, hypoxic,
and inflammatory). Two regions, CA1 region and the DG, were
examined in parallel. For biochemical studies, these regions were
dissected separately under a low magnification microscope,
whereas the total hippocampal complex, part of the entorhinal cor-
tex, and the lower temporal gyrus were included in the same bloc
for morphological studies. A summary of the cases analyzed is
shown in Supporting Information Table I.
RNA purification
Total RNA of the CA1 and DG was isolated using the RNeasy
Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) according to the
protocol of the supplier. Samples were treated with RNase-free
DNase Set (Qiagen) for 15 minutes to avoid extraction and later
Table 1. mRNA expression of nucleolar proteins and 18S rRNA and 28S rRNA in the DG and CA1 region of the hippocampus of MA and AD
cases.
Probe MA AD I–II AD III–IV AD V–VI MA vs. AD I–II MA vs. AD III–IV MA vs. AD V–VI
DG
NCL 1.01 6 0.18 1.19 6 0,19 0.98 6 0,23 0.91 6 0.26 NS NS NS
NPM1 1.01 6 0.17 1.07 6 0.22 1.01 6 0.22 0.67 6 0.20 NS NS **#
NPM3 1.17 6 0.19 0.91 6 0.14 0.99 6 0.15 0.64 6 0.09 NS NS *#
UBTF 1.02 6 0.22 0.76 6 0.25 0.81 6 0.19 0.25 6 0.08 NS NS ***#
CA1
NCL 1.04 6 0.30 1.22 6 0.12 1.09 6 0.37 0.58 6 0.20 NS NS **#
NPM1 1.02 6 0.25 1.36 6 0.12 1.35 6 0.17 1.04 6 0.30 *" *" NS
NPM3 1.06 6 0.10 1.09 6 0.10 1.49 6 0.15 0.57 6 0.07 NS *" **#
UBTF 1.05 6 0.35 0.54 6 0.14 0.60 6 0.13 0.59 6 0.16 ***# **# **#
DG
18S rRNA 1.04 6 0.34 0.74 6 0.11 0.80 6 0.40 1.13 6 0.22 NS NS NS
28S rRNA 1.10 6 0.52 0.66 6 0.17 0.47 6 0.19 1.90 6 0.63 NS **# NS
CA1
18S rRNA 1.10 6 0.45 0.65 6 0.36 1.13 6 0.11 1.51 6 0.31 NS NS NS
28S rRNA 1.15 6 0.67 0.45 6 0.19 0.43 6 0.22 2.65 6 0.85 *# *# **"
Expression levels are calculated using Gus-b for normalization; Student t-test *P< 0.05; **P< 0.01; ***P< 0.001 compared with MA.
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amplification of genomic DNA. The RNA concentration of each
sample was measured at A260 nm using a NanoDrop 2000 spectro-
photometer (Thermo-Scientific, Waltham, MA, USA). RNA integ-
rity number (RIN) was calculated using the Agilent 2100
Bioanalyzer (Agilent, Santa Clara, CA, USA). The RIN values of
the samples varied from 6.3 to 7.9.
cDNA synthesis
The reverse transcription reaction of RNA was performed with the
High-Capacity cDNA Archive kit (Applied Biosystems, Foster City,
CA, USA) following the manufacturer’s guidelines and using a Gene
Amp 9700 PCR System thermo-cycler (Applied Biosystems). To test
for the presence of contaminating DNA, a parallel reaction in one
RNA sample was run in the absence of reverse transcriptase.
TaqMan PCR
Samples analyzed with TaqMan polymerase chain reaction (PCR)
comprised 14 controls (7 women, 7 men) and 28 AD cases (14
women, 14 men) (Table 1). TaqMan PCR assays were performed
on 384 optical plates utilizing the ABI Prism 7900 HT Sequence
Detection System (Applied Biosystems). The cDNA samples
obtained from the retro-transcription reaction were diluted 1:20,
and TaqMan PCR assays for each gene were performedin dupli-
cate. For each TaqMan reaction, 9 mL of cDNA was mixed with 1
mL 20X TaqMan Gene Expression Assay and 10 mL of 2X Taq-
Man Universal PCR Master Mix (Applied Biosystems). The reac-
tions were performed as follows: 508C for 2 minutes, 958C for 10
minutes and 40 cycles at 958C for 15 s and 608C for 1 minutes.
TaqMan PCR data were captured using the Sequence Detection
Software (SDS version 2.2, Applied Biosystems). TaqMan probes
used in the study are shown in Supporting Information Table II.
Parallel assays for each sample were performed using TaqMan
probes for b-glucuronidase (GUS-b) and X-prolyl aminopepidase
P1 (XPNPEP1) as endogenous controls.
For the data analysis, threshold cycle (CT) values for each sam-
ple were processed to obtain double delta CT ( DDCT) values.
First, delta CT (DCT) values were calculated as the normalized CT
values for each target gene in relation to the CT of endogenous
controls GUS-b and XPNPEP1. Then, DDCT values were obtained
from the DCT of each sample minus the mean DCT of the popula-
tion of control samples (calibrator samples). The fold change was
calculated using the equation 2(2DDCT). Mean fold-change values
for each region and experimental group were analyzed with Stu-
dent-t test using the Graph Pad Prism 5 Software. Differences
between AD stages and MA group were considered statistically sig-
nificant at *P< 0.05, **P< 0.01, and ***P< 0.001.
Immunohistochemistry
Inmunohistochemical assessment was performed on 4-mm-thick
dewaxed paraffin sections obtained with a sliding microtome. The
sections were boiled in citrate buffer (10 mM sodium citrate, pH
6.0) for 20 minutes to retrieve antigens and then washed with PBS.
Then, endogenous peroxidases were blocked with Dako Peroxidase
Blocking Reagent (DAKO, Glostrup, Denmark) for 10 minutes.
Primary antibodies were diluted in Dako Antibody Diluent (DAKO
Corporation, USA) and incubated overnight at 48C (see Supporting
Information Table III for details). After incubation with the primary
antibody and PBS rinses, sections were incubated at room tempera-
ture with the Super SensitiveTM link-label IHC Detection System
(Biogenex, Fremont, CA, USA) according to the manufacturer’s
instructions. The peroxidase reaction was visualized with 303-
diaminobenzidine (Liquid DAB1 Substrate Chromogen System,
DAKO Corporation, USA). Finally, the sections were dehydrated
and cover-slipped for microscopic observation. To test the specific-
ity of immunoreaction some sections were incubated without the
primary antibodies; the staining was negative.
Cell counting
Histological sections were captured with a ProgRes camera (Jenop-
tik, Germany) attached to a Nikon Eclipse E800 microscope
(Tokyo, Japan). Cell counting was performed on 4-mm-thick sec-
tions corresponding to DG and CA1, from four to six cases per
group. The number of positive cells for different markers was
recorded in three optical fields at 400X magnification. Mean data
were analyzed with one-way ANOVA followed by Tukey’s test
post hoc analysis. Statistical examination was performed in Graph
Pad Prism 5. Differences between MA and AD groups were con-
sidered significant at *P< 0.05, **P< 0.01 and ***P< 0.001.
Western blotting
Tissue samples of CA1 (0.1 g) were homogenized in 1 mL of Mila
lysis buffer (100 mM Tris/HCl buffer pH 7.4, containing 100 mM
NaCl, 10 mM ethylenediaminetetraacetate (EDTA), 0.5% sodium
deoxycholate, 0.5% Nonidet-P40, and protease and phosphatase
inhibitor cocktails), and then centrifuged at 48C for 10 minutes at
5000 rpm. The protein content was quantified with the Bradford
method. Afterwards, 20 mg of protein was loaded into a 12% SDS-
PAGE and then electrophoresis proteins were transferred to nitro-
cellulose membranes. Membranes were blocked with TBS contain-
ing 5% non-fat dry milk and 0.1% Tween 20 for 1 h at room
temperature and then incubated overnight at 48C with the appropri-
ate primary antibody (Table 3). After washing with TBS/
0.1%Tween 20, the membranes were incubated for 1 h at room
temperature with the corresponding horseradish peroxidase-
conjugated secondary anti-body (1:2000; Dako) (Table 3), and the
immune complexes were detected by chemiluminescence (ECL,
Amersham, Fairfield, CT, USA). The densitometric analysis of
western blot bands was conducted using the NIH ImageJ software
(Bethesda, MD, USA). Densitometric protein values were normal-
ized with b-actin levels and expressed as an optical density ratio.
Statistical differences between MA and AD groups were analyzed
with one-way analysis of variance (ANOVA) followed by Tukey’s
test post hoc analysis. Statistical examination was performed in
Graph Pad Prism 5. Differences were considered significant at
*P< 0.05, **P< 0.01 and ***P< 0.001.
RESULTS
Changes in mRNA expression and protein levels
of nucleolar genes in DG and CA1 of AD
No modifications in the mRNA expression levels of nucleolin
(NCL), nucleophosmin (NPM1), nucleoplasmin 3 (NPM3) and
upstream binding transcription factor, RNA polymerase I (UBTF)
were observed in the DG of AD cases at stages I–II and III–IV
when compared with MA. However, significantly reduced
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expression of NPM1, NPM3 and UBTF mRNAs was seen in the
DG of AD cases at stages V–VI (Table 1).
Regarding the CA1 region, NPM1 up-regulation and UBTF
down-regulation were observed in AD at stages I–II and III–IV
when compared with MA cases. In addition, NPM3 mRNA was
up-regulated at stages III–IV (Table 1). This was followed by sig-
nificantly reduced expression of NCL, NPM3 and UBTF mRNAs,
and normal NPM1 mRNA levels at stages V–VI (Table 1).
Immunohistochemistry further revealed alterations in level and
distribution of nucleolar proteins with disease progression. NPM1
antibodies decorated the nucleolus of CA1 neurons in MA individ-
uals but NPM1 immunoreactivity decreased in the nucleolus of
CA1 neurons along disease progression, with the immunostaining
being very weak at stages V–VI (Figure 1A–D). NPM1 immunore-
activity also decreased in DG. A nucleolar pattern was also
observed for NPM3 in CA1 and DG. NPM3 immunoreactivity pro-
gressively faded in the nucleolus of CA1 and DG neurons with dis-
ease progression (Figure 1E–H). NCL immunohistochemistry
revealed a particular pattern in MA brains, in addition to the weak
nucleolar immunostaining, a few CA1 neurons showed cytoplasmic
immunoreactivity. Decreased nucleolar immunostaining in CA1
neurons with disease progression was also observed for NCL. Curi-
ously, NCL was localized in cytoplasmic granules recognized as
granulovacuolar degeneration in CA1 neurons at advanced stages
of AD (Figure 1I–K).
UBF (the product encoded by UBTF) immunoreactivity was
observed in the nucleolus of CA1 neurons and of neurons of the
entorhinal cortex and inner temporal neocortex, but it was dispersed
in the nucleus of the DG granule cells in MA individuals (Figure
2A–D). Nucleolar and diffuse nuclear UBF immunoreactivity
decreased with AD progression (Figure 2E–L). In addition, UBF
immunoreactivity translocated to the cytoplasm and was integrated
into NFTs but not in dystrophic neurites of senile plaques (Figure
2E–L).
Considering the total number of nucleoli in a particular section
those stained with Nissl stain, quantification of stained nuclei with
antibodies anti-NPM1, NPM3, NCL and UBF revealed a signifi-
cant decrease (ranging from P< 0.05 to P< 0.001) in the immuno-
reactivity of all these markers in CA1 and DG with AD
progression. Quantitative values of these changes at different stages
of AD are shown in Table 2.
Importantly, no immunohischemical differences regarding
NPM1, NPM3, NCL and UBF were seen between MA individuals
and AD cases at stages I–II in DG and CA1. However, reduced
numbers of nucleoli, as revealed with Nissl stain, and reduced num-
bers of NPM1, NPM3, NCL and UBF-immunoreactive nucleoli
was observed in CA1 at stages III–IV, and more markedly at stages
V–VI (Table 2). A similar pattern, although less severe, was seen
in DG (Table 2). Detailed inspection of figures revealed that, in
addition to reduced numbers of immunoreactive nucleoli,
Figure 1. NPM1, NPM3 and NCL in MA cases and AD at different
stages of disease progression. A–D. NPM1/B23 in CA1 (A–D), in MA
(A) and AD cases stages I–II (B), III–IV (C) and V–VI (D). E–H. NPM3
in the CA1 region of the hippocampus in MA (E), AD stage I-II (F), IV
(G) and V (H) of Braak and Braak. I–K. Nucleolin in CA1 in MA (I) and
AD stage V–VI (J, K). Decreased numbers of nucleoli and reduced
nucleolar NPM1, NPM3 and NCL immunoreactivity in remaining nucle-
oli is observed in neurons at stages III–IV and V–VI when compared
with MA and AD cases stages I–II. A few CA1 neurons show, in addi-
tion to weak nucleolar staining, NCL immunoreactivity. Cytoplasmic
granules in neurons with granulovacuolar degeneration are strongly
NCL immunoreactive. Paraffin sections without haematoxylin counter-
staining permit a perfect visualization of the nucleolus, bar 5 25 mm.
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Figure 2. UBF in MA cases and AD at different stages of disease
progression. A–D. MA; E–H. AD stage III–IV; I–L. AD stage V–VI of
Braak and Braak. A, E, I: CA1 region of the hippocampus; B, F, J:
dentate gyrus; C, G, K: entorhinal cortex; D, H, L: temporal cortex.
UBF-immunoreactive nucleoli decrease and UBF nucleolar immuno-
staining fades at staged III–IV and V–VI when compared with MA
cases. This is particularly evident in neurons bearing NFTs. Moreover
UBF immunoreactivity locates to the cytoplasm and decorates NFTs.
Paraffin sections without haematoxylin counterstaining, bar 5 25 mm.
Table 2. Quantification of nucleoli in CA1 and DG in MA and AD at different stages of disease progression as revealed with Nissl staining and
with NPM1, NPM3, NCL and UBF immunohistochemistry. Quantification of positive nuclei as revealed with antibodies anti-H3K9me2, H4K12ac
and tau-100.
Marker MA AD I–II AD III–IV AD V–VI MA vs. AD I–II MA vs. AD III–IV MA vs. AD V–VI
DG
Nissl 108.28 6 1.07 104.33 6 0.85 101.17 6 1.01 95.83 6 1.28 NS *# ***#
NPM1 109.00 6 3.40 107.67 6 3.37 98.33 6 3.28 94.42 6 2.87 NS NS * #
NPM3 115.34 6 2.95 110.59 6 2.20 102.67 6 2.51 93.08 6 2.30 NS **# ***#
NCL 116.50 6 1.84 115.75 6 1.71 108.67 6 1.37 100.33 6 2.93 NS NS **#
UBF 115.33 6 2.91 106.89 6 1.55 98.00 6 3.29 91.00 6 2.24 NS **# ***#
tau-100 114.30 6 1.18 108.50 6 2.47 102.60 6 1.70 94.13 6 2.16 NS *# ***#
H3K9me2 109.88 6 2.33 100.92 6 0.71 93.50 6 1.52 87.25 6 1.57 *# ***# ***#
H4K12ac 111.13 6 1.20 107.58 6 1.71 97.04 6 2.12 89.58 6 1.20 NS ***# ***#
CA1
Nissl 36.96 6 1.04 34.30 6 0.75 31.28 6 1.30 27.92 6 1.08 NS *# **#
NPM1 40.88 6 0.86 38.29 6 1.56 33.94 6 1.60 27.63 6 0.95 NS *# ***#
NPM3 40.50 6 1.10 39.25 6 1.17 35.08 6 1.36 27.58 6 1.21 NS *# ***#
NCL 41.17 6 0.87 38.58 6 0.76 33.42 6 1.52 28.89 6 0.78 NS **# ***#
UBF 39.22 6 1.06 37.17 6 1.16 31.11 6 0.97 26.27 6 0.48 NS **# ***#
tau-100 41.92 6 1.08 36.63 6 0.98 30.17 6 1.09 27.28 6 1.01 NS ***# ***#
H3K9me2 38.13 6 1.33 32.33 6 0.89 29.28 6 0.72 26.75 6 0.89 *# ***# ***#
H4K12ac 39.00 6 1.08 36.30 6 0.78 30.50 6 1.06 28.04 6 0.53 NS ***# ***#
Data are expressed as the mean 6 Standard error of the mean (SEM) of four to six cases per group; one-way ANOVA followed by Tukey’s test
post hoc analysis *P< 0.05, **P< 0.01, ***P< 0.001.
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individual remaining nucleoli showed reduced immunoreactivity at
AD stages III–IV and V–VI (Figure 1).
Modifications of histones and nuclear tau in DG
and CA1 in AD
NCL and NPMs regulate rRNA transcription through the modula-
tion of histone modifications dimethylated histone H3K9
(H3K9me2) and acetylated histone H3K12 (H3K12ac) in rRNA
genes (18, 98). To learn whether NCL and NPM3 changes were
associated to modifications in histone methylation and acetylation
in AD, immunohistochemistry to specific methylated and acety-
lated sites in those histones was performed in the same samples.
H3K9me2 (Figure 3A–D) and H4K12ac (Figure 3E–H) staining
declined in CA1 and DG neurons with disease progression (Table
2). Moreover, H4K12ac-immunoreactive globules and bars in the
neuropil of the hippocampus were noted at advanced stages of AD
(Figure 3G,H).
Non-phosphorylated tau is present at the internal periphery of
nucleoli and the nucleus (87). Accordingly, tau-100 antibody
stained the nuclei of neurons and glial cells of CA1, DG, hilus,
entorhinal cortex and temporal cortex in MA brains (Figure
4A,E,I,M,O). Decreased tau-100 nuclear immunoreactivity was
observed in all these regions in AD with disease progression. This
was accompanied by translocated tau-100 immunoreactivity to
NFTs and dystrophic neurites of senile plaques in CA1, entorhinal
cortex and temporal neocortex (Figure 4A–P). Interestingly,
although nuclear tau-100 immunoreactivity was reduced in all these
regions, only total disappearance of tau-100 in the nucleus paral-
leled cytoplasmic tau accumulation in NFTs (Figure 4C,D,L,N,P).
Quantitative data are shown in Table 2.
rRNAs in DG and CA1 of AD
Subunit 18 ribosomal RNA (18S rRNA) was not significantly
altered in the DG in AD when compared with MA cases. However,
subunit 28 ribosomal RNA (28S rRNA) was down-regulated in the
DG in AD stages III-IV in relation to MA cases. Regarding CA1,
no modifications in 18S rRNA expression levels were found at any
stage; 28S rRNA was reduced in AD I–II and AD III–IV but it was
found to be up-regulated at AD stages V–VI compared with MA
(Table 1).
mRNA expression of ribosomal proteins in DG
and CA1 of AD
mRNA levels of RPL23A, RPL26, RPL31, RPS5, RPS6, RPS10
and RPS13 were down-regulated in the DG in AD I–II compared
with MA; and mRNAs of RPL21, RPL23A, RPL27, RPS5, RPS6,
RPS10, and RPS13 in AD III–IV in comparison with MA. RPL7,
RPL21, RPL26, RPL27, RPL31, RPS10, RPS16 and RPS17 mRNA
levels were significantly down-regulated and RPL22 up-regulated
in DG at stages V–VI when compared with MA cases (Table 3).
Regarding CA1, RPL5 and RPL26 mRNAs were up-regulated
and RPS5 and RPS26 mRNAs down-regulated in AD I-II in rela-
tion to MA cases. RPL5 mRNA was up-regulated and RPL23A and
RPS5 down-regulated at stages II–IV. RPL5 and RPL30 mRNAs
were up-regulated at stages V–VI, but RPL21, RPL23A, RPL26,
RPL31, RPS6, RPS10, RPS13, RPS16 and RPS17 significantly
down-regulated at stages V–VI (Table 3).
Translation initiation and elongation factors
in CA1 of AD
Western blotting was used to assess the protein levels of initiation
factors eIF2a, eIF3h, and eIF5 and elongation factors eEF1A and
eEF2 in the CA1 region in MA and AD cases at different stages of
disease progression. The small size of the DG did not permit the
use of available frozen samples for these protein studies.
Increased eIF2a protein levels were found at stages III–IV and
V–VI, whereas decreased expression of eIF3h occurred in parallel
at the same stages of AD. A slight reduction in eIF5 was found
only at stages III–IV (Figure 5A).
Reduced eEF2 protein levels were identified only at stages I–II
and normalized thereafter. No modifications in the expression lev-
els of eEF1A were noted with disease progression (Figure 5B).
Figure 3. Histone modifications in AD. A–D. H3K9m2, E–H.
H4K12ac; CA1 region of the hippocampus. A, E: MA individuals; AD
stages I–II (B), III–IV (C, F) and V–VI (D, G, H). Individual selective loss
of nuclear neuronal immunoreactivity and rare formation of H4K12ac-
immunoreactive globules and bars at advanced stages of AD. Paraffin
sections without haematoxylin counterstaining, bar 5 25 mm
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DISCUSSION
This study shows altered mRNA expression and protein levels of
crucial players in the process of protein synthesis, from the nucleo-
lus to the ribosomes, in the DG and CA1 region of the hippocam-
pus of AD cases at different stages of disease progression when
compared with MA individuals with no neurological alterations
and no AD-related pathology.
Nucleolar alterations
NCL, NPM1/B23 and NPM3 are major nucleolar proteins acting as
histone-binding chaperones required for chromatin compacting and
regulation of rRNA transcription (2, 18, 33, 37, 40, 41, 53, 65, 72,
74, 77, 97, 102, 104). NPM1 interacts with histones H3 and H4,
and it is capable of nucleic acid binding (31, 77, 98). NPM1 is also
involved in chromatin de-condensation, post-translational modifica-
tion of histones, and nuclear re-programming (98). In addition,
NPM1 is involved in the nuclear transport of proteins to the nucleo-
lus and certain ribosomal proteins to the cytoplasm (6, 95, 96, 109).
Additional functions of NPM1 are related to DNA replication, ribo-
some biogenesis, transcription, and repair (65). UBF encoded by
UBTF (upstream binding transcription factor, RNA polymerase I
gene) is associated with NOR and is required for rDNA transcrip-
tion by RNA polymerase 1 (83). It is known that altered expression
of nucleolar chaperones and factors involved in rRNA synthesis
results in nucleolar stress which in turn leads to impaired ribosomal
biogenesis (4, 58, 69, 79). The present observations show nucleolar
stress in the hippocampus, mainly in CA1 but also in DG, in AD.
Importantly, altered NPM1 and UBTF gene expression is already
observed in CA1 at stages I–II. Reduced NPM1, NPM3, NCL and
UBF protein levels are seen in CA1 at stages III–IV (Tables 1 and
2). Therefore, nucleolar alterations in AD are probably not a mere
consequence of cell death as altered mRNA regulation of NPM1
Figure 4. Tau-100 immunohistochemistry. A–D. CA1 region of the
hippocampus; E–H. dentate gyrus; I–L. hilus; M, N. entorhinal cortex;
O, P. temporal cortex layer V. A, E, I, M: Middle-aged (MA); B, F, J:
AD stage II of Braak and Braak; C, G, K, N: stage III of Braak; D, H, L,
P: stage V. Tau-100 immunoreactivity is present in the nucleus of neu-
rons and glial cells in MA brains. Decreased tau-100 nuclear immuno-
reactivity occurs in AD with disease progression. Almost complete
absence of tau-100 immunoreactivity in the nucleus is seen in neu-
rons with NFTs in CA1, entorhinal cortex, and temporal neocortex.
Note that reduced nuclear tau-100 immunoreactivity is not necessarily
accompanied by NFT formation. Tau-100 also decorates dystrophic
neurites of senile plaques (D). Paraffin sections without haematoxylin
counterstaining, bar 5 25 mm
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and UBTF first occurs before any evidence of neuron loss in the
CA1 region of the hippocampus at stages I–II. Lack of perfect
match between mRNA levels and corresponding proteins, as seen
in relation with increased NPM1 and NPM3 mRNAs and decreased
NPM1 and NPM3 protein levels in the CA1 region of the hippo-
campus at stages III–IV, is not rare in human neurodegenerative
diseases and can be explained by the concomitant activity of epige-
netic factors as several types of non-coding RNAs. Reduced num-
bers of nucleoli as revealed with Nissl staining together with
significant decreased numbers of NPM1-, NPM3-, NCL- and UBF-
immunoreactive nucleoli is consistent, in part, with neuron loss at
stages III–IV and V–VI. In addition, immunohistochemistry shows
reduced immunoreactivity in remaining nucleoli at middle and
advanced stages of the disease thus suggesting declining immuno-
reactivity in surviving cells.
Nucleolar alterations in AD are accompanied by altered regula-
tion of rRNA expression. Thus, 28S rRNA in CA1 is down-
regulated at stages I–IV and up-regulated at stages V–VI compared
with MA and 28S rRNA in the DG is transiently down-regulated at
stages III–IV in AD. As alterations of NCL, NPMs and UBF
increase with disease progression whereas alterations of rRNA vary
along disease, other factors, as epigenetic regulation of rDNA (80),
are probably implicated in the altered rRNA biogenesis in AD. In
this line, it is particularly intriguing and unresolved the increased
expression levels of 28S rRNA in the CA1 region at advanced
stages of AD and the transient decrease of 28S rRNA in DG. How-
ever, it is well known that oxidative damage to mRNA, tRNA and
rRNA occurs in AD and that such damage may produce ribosomal
dysfunction and altered protein synthesis (26, 27, 48, 75, 76, 90,
91). As a working hypothesis, it can be postulated that oxidative
damage to RNA triggers epigenetic responses which in turn modu-
late by activation or by repression the expression of variegated mol-
ecules implicated in ribosomal biogenesis.
Nuclear alterations
Regarding the nucleus, NCL and NPMs regulate rRNA transcrip-
tion through the modulation of H3K9m2 and H4K12ac in rRNA
genes (18, 98). H3K9me2 and H4K12ac nuclear immunoreactivity
declines in CA1 and DG with AD progression thus suggesting that
specific post-translational modifications of selected histones which
Table 3. mRNA expression of ribosomal proteins in the DG and CA1 region of the hippocampus of MA and AD cases.
Probe MA AD I–II AD III–IV AD V–VI MA vs. AD I–II MA vs. AD III–IV MA vs. AD V–VI
DG
RPL5 1.02 6 0.23 0.94 6 0.16 0.95 6 0.19 0.97 6 0.21 NS NS NS
RPL7 1.02 6 0.22 0.91 6 0.34 1.05 6 0.26 0.41 6 0.07 NS NS ***#
RPL21 1.02 6 0,23 0.71 6 0.38 0.80 6 0.08 0.31 6 0.08 NS *# ***#
RPL22 1.07 6 0.44 0.92 6 0.43 0.92 6 0.22 1.55 6 0.12 NS NS *"
RPL23A 1.02 6 0.24 0.61 6 0.24 0.76 6 0.22 0.81 6 0.15 *# *# NS
RPL26 1.07 6 0.41 0.64 6 0.32 0.74 6 0.30 0.50 6 0.24 *# NS **#
RPL27 1.03 6 0.29 0.70 6 0.26 0.75 6 0.16 0.34 6 0.09 NS *# ***#
RPL30 1.07 6 0.43 0.70 6 0.08 0.77 6 0.18 0.96 6 0.29 NS NS NS
RPL31 1.03 6 0.27 0.64 6 0.25 0.83 6 0.22 0.54 6 0.14 *# NS ***#
RPS3A 1.04 6 0.30 0.98 6 0.04 0.96 6 0.19 0.96 6 0.15 NS NS NS
RPS5 1.01 6 0.20 0.66 6 0.15 0.76 6 0.14 0.96 6 0.32 *# *# NS
RPS6 1.00 6 0.11 0.80 6 0.17 0.82 6 0.18 0.88 6 0.21 *# *# NS
RPS10 1.01 6 0.19 0.65 6 0.08 0.74 6 0.13 0.62 6 0.10 **# **# ***#
RPS13 1.02 6 0.22 0.78 6 0.39 0.75 6 0.12 0.79 6 0.10 *# *# NS
RPS16 1.03 6 0.31 0.79 6 0.39 0.72 6 0.30 0.68 6 0.26 NS NS *#
RPS17 1.01 6 0.14 0.82 6 0.15 0.93 6 0.20 0.48 6 0.09 NS NS ***#
CA1
RPL5 1.02 6 0.23 1.33 6 0.07 1.27 6 0.15 1.33 6 0.25 **" *" *"
RPL7 1.04 6 0.31 1.28 6 0.20 1.30 6 0.13 0.78 6 0.12 NS NS NS
RPL21 1.04 6 0.33 0.91 6 0.30 0.79 6 0.11 0.41 6 0.25 NS NS ***#
RPL22 1.07 6 0.48 0.84 6 0.15 0.88 6 0.21 0.70 6 0.08 NS NS NS
RPL23A 1.04 6 0.31 0.78 6 0.26 0.67 6 0.15 0.59 6 0.08 NS **# **#
RPL26 1.09 6 0.46 1.60 6 0.19 1.14 6 0.40 0.53 6 0.21 *" NS *#
RPL27 1.04 6 0.33 0.86 6 0.21 1.06 6 0.15 1.05 6 0.15 NS NS NS
RPL30 1.03 6 0.27 0.81 6 0.21 1.12 6 0.32 1.70 6 0.29 NS NS ***"
RPL31 1.04 6 0.33 0.90 6 0.12 1.09 6 0.19 0.55 6 0.16 NS NS **#
RPS3A 1.06 6 0.40 0.96 6 0.11 1.24 6 0.13 1.05 6 0.23 NS NS NS
RPS5 1.04 6 0.29 0.75 6 0.18 0.81 6 0.14 0.89 6 0.10 *# *# NS
RPS6 1.06 6 0.36 0.66 6 0.20 0.84 6 0.12 0.49 6 0.08 *# NS ***#
RPS10 1.05 6 0.34 0.84 6 0.16 0.98 6 0.17 0.65 6 0.13 NS NS *#
RPS13 1.04 6 0.30 1.01 6 0.21 1.19 6 0.22 0.17 6 0.04 NS NS ***#
RPS16 1.08 6 0.38 0.97 6 0.25 1.01 6 0.59 0.09 6 0.03 NS NS *#
RPS17 1.01 6 0.14 0.98 6 0.19 1.11 6 0.23 0.26 6 0.05 NS NS *#
Expression levels are calculated using Gus-b for normalization; Student t-test *P< 0.05; **P< 0.01; ***P< 0.001 compared with MA.
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are involved in rRNA synthesis are altered in hippocampus neurons
in AD.
Protein tau is localized in the nucleus of neuroblastoma cells
(44, 45, 66, 100, 105), non-neural cells (21, 68, 101), and neurons
in human brain (14). Tau binds to double- and single-strands of
DNA in vitro (51, 61, 78) and both the proline-rich domain and the
microtubule-binding domain of tau are known to contribute to its
interaction with DNA (107). Nuclear tau induces DNA conforma-
tional changes in neural cells (81), protects DNA from denaturation
in vitro (51, 52), prevents DNA damage by oxidative stress (94,
106), and confers stability to DNA (15, 92). Histone deacetylase 6
interacts with the microtubule-associated protein tau (25).The pres-
ent data illustrate a marked decrease of nuclear tau-100 in CA1 and
DG neurons with disease progression. Nuclear tau-100 virtually
disappears in neurons with NFTs. This is a very important point as
it has been postulated that tau promotes neurodegeneration through
global chromatin relaxation in AD because increased tau hyper-
phosphorylation and tangle formation in the cytoplasm parallels
chromatin disassembly (39). Although such explanation may be
correct, the present findings offer an additional scenario: tau accu-
mulation in NFTs is only one of the terminal stages of tau metabo-
lism disruption in AD. Decreased levels of nuclear tau precede
cytoplasmic tau hyper-phosphorylation. Moreover, decreased
nuclear tau is not restricted to neurons with NFTs. Therefore,
reduced nuclear tau is a distinct alteration of tau metabolism in AD.
As a working hypothesis, it can be suggested that it is not the accu-
mulation of cytoplasmic hyper-phosphorylated tau which disassem-
bles chromatin but rather it is the decrease in nuclear tau that is
responsible for DNA disassembly. Eventually, nuclear tau is no
longer present in neurons with NFTs. The relationship between
reduced nuclear tau, histone modifications and chromatin relaxation
is, at present, under study.
Altered ribosomes
Ribosomes are composed of 65% RNAs and 35% ribosomal pro-
teins that form the small subunit (40S) which binds to mRNA and
the large subunit (60S) which binds to tRNAs and amino acids. In
eukaryotes, the small subunit is made of 18S rRNA and 33 proteins
whereas the larger subunit consists of 5S rRNA, 5.8S rRNA, 28S
rRNA, and 46 ribosomal proteins (19, 29, 30, 38, 42, 43, 46, 59,
60, 93, 108). Eleven of sixteen mRNAs encoding ribosomal pro-
teins examined here are altered in CA1 in AD at stage V–VI, and
nine of sixteen in the DG at the same AD stage. It can be suggested
that down-regulation of ribosomal protein genes is the result of
neuron loss at advanced stages of the disease, but 3 RPLs and 4
RPSs are down-regulated in the DG and two RPLs and two RPSs
are up- and down-regulated, respectively in CA1 in AD stages I–II
of Braak and Braak. Therefore, altered gene expression of ribo-
somal proteins occurs before the appearance of cell death. Nucleo-
lar stress, a well-known disturbing factor of ribosomal biogenesis
(71), can be considered as a putative inducing factor of altered ribo-
somal gene expression at early stages of AD.
Altered expression of factors involved
in protein biosynthesis
Translation initiation in the ribosome is geared by the interactions
of 12 eukaryotic translation initiation factors (eIFs), most of them
composed of several subunits (55, 57). Elongation occurs when
elongating factor eEF1A is activated following GTP binding and
Figure 5. Eukaryotic translation factors in the CA1 region of MA and AD
cases. A. Representative western blots and densitometric analysis of the
content of eIF2 a, eIF3g, eiF5 in the CA1 region of MA, AD I–II, AD III–IV,
and AD V–VI cases. B. Western blot analysis of eEF1A and eEF2 in the
CA1 region of MA, AD I–II, AD III–IV, and AD V–VI cases. b-actin levels are
used to normalize total protein content. The values represent the mean-
6 standard error of the mean (SEM) of 6–7 cases for group. *P> 0.05,
**P> 0.01 compared with MA.
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forms a complex with aminoacyl-tRNA which recognizes the spe-
cific sequence in mRNA at the ribosome. Once the interaction of
the codon in mRNA with the anti-codon in tRNA is decoded,
eEF1A-GDP is hydrolysed, released from the ribosome, and
recycled into its active form by eEF1B. eEF2 assists in the precise
codon location at the ribosome (1, 24, 70, 73, 85, 103).eIF3h and
eIF5 protein levels are reduced whereas eIF2a protein levels are
increased in the CA1 region of the hippocampus in AD with dis-
ease progression. Increased eIF2a correlates with increased p-
eIF2a in AD as previously reported (17, 34, 49, 50). Phosphoryla-
tion of eIF2 on its a subunit prevents the delivery of initiator
methionyl-tRNA, resulting in global inhibition of translation of
most mRNAs (47). Together these observations support altered
protein synthesis with disease progression.
Final comments
Several studies have shown altered gene expression in the post-
mortem brain of cases with AD and related animal models (7, 67,
99). However, this is the first study showing altered pathways
related to protein synthesis including altered mRNA and protein
expression of certain nucleolar chaperones, factors linked to DNA
polymerases, altered methylation and acetylation of specific histo-
nes, altered expression of nuclear tau, abnormal rRNA expression,
altered expression of several RPL and RPS genes, and altered
expression of certain initiation and elongation factors of protein
synthesis at the ribosome in the AD hippocampus.
It can be argued that none of these alterations proves that protein
synthesis is impaired in AD. However, analysis of protein synthesis
using incorporation of labeled amino acids to proteins in post-
mortem human brain samples has been unsuccessful. Very low and
erratic incorporation of S35 methionine into protein has made
impossible to replicate previous experiments performed by other
authors (26, 27).
As mentioned in previous paragraphs, not all these changes can
be linked to neuronal loss as they first appear at stages in which no
cell death is found in the hippocampus in AD. It is worth stressing
that the expression of NPM1 and UBTF mRNAs, 28sRNA, RPL5,
RPL26, RPS5 and RPS6 mRNAs, and eEF2 protein is altered in the
CA1 at stages I–II of Braak and Braak. RPL23A, RPL26, RPL31,
RPS5, RPS6, RPS10 and RPS13 mRNAs are down-regulated in
DG at stages I–II. Therefore, the present findings show also for the
first time that multiple alterations in pathways involved in protein
synthesis occur at very early stages of cases with AD-related
pathology, before the appearance of clinical symptoms if they
would ever have appeared (35). Finally, it is important to note that
changes in AD differ in the CA1 and DG at the beginning and
along disease progression. The reason of regional vulnerability in
neurodegenerative diseases is a long-lasting non-solved question
that is the subject of continuous attention.
Progressive atrophy of the hippocampus, as visualized with sev-
eral neuroimaging techniques and in a particular clinical context, is
currently used as a biomarker of AD progression (8). This change
has been mainly interpreted as being the result of loss of afferents
to the DG and to the loss of neurons in the CA1 region of the hip-
pocampus (107). However, morphological and immunohistochemi-
cal studies have shown reduced dendritic arbors, reduced numbers
of synapses, and reduced synaptic protein markers both in the CA1
region of the hippocampus and in the DG (32, 36, 56, 82, 86–89).
The present observations may help to improve understanding of
neuronal atrophy in CA1 and DG in AD resulting from altered
molecular machinery of protein synthesis involving specific path-
ways in the nucleolus, nucleus and ribosome.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Table I. Summary of cases and methods used in the present
series. Age in years, p-m delay: post-mortem delay; MA:
middle-aged without neurological and mental disease and no
alterations in the neuropathological study, AD: Alzheimer’s dis-
eases stages of Braak and Braak; ih: immunohistochemistry,
wb: western blotting.
Table II. TaqMan probes. Gene abbreviation, full name and
sequence.
Table III. Characteristics of antibodies. rb: rabbit polyclonal,
ms: mouse monoclonal, ih: immunohistochemistry, wb: western
blotting.
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